SCHEMBL12401142

SCHEMBL12401142

CC(C)(C)C(=O)CC1CCN(Cc2c(Cl)cccc2Cl)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 6/20 0.53
KDM4E B2RXH2 4/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
CYP2A13 Q16696 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 2/20 0.43
DRD4 P21917 1/20 0.43
ACKR3 P25106 1/20 0.43
ACHE P22303 1/20 0.42
ALOX15 P16050 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8237166 0.85 CXCR4 (0.56) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL2445773 0.83 CXCR4 (0.54) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL15338728 0.82 CXCR4 (0.53) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL12401074 0.82 ACHE (0.60) CXCR4ACHE
SCHEMBL19084133 0.77 CYP2A13 (0.56) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL19083687 0.74 ACHE (0.61) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL28551278 0.73 CYP2A13 (0.54) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL16978124 0.72 EPHX1 (0.48) SMN1; SMN2
SCHEMBL6944902 0.70 CYP2A13 (0.59) CXCR4KDM4EPOLBTSHRSMN1; SMN2
SCHEMBL19075616 0.70 CYP2A13 (0.54) CXCR4KDM4EPOLBTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575208-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 CXCR4 3814/4885KDM4E 2603/4885POLB 3945/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 CXCR4 3814/4885KDM4E 2603/4885POLB 3945/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 CXCR4 2147/4885KDM4E 1721/4885POLB 2644/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CXCR4 3634/4885KDM4E 1669/4885POLB 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.